Amgen/AstraZeneca’s Tezspire Shows Efficacy In Broader COPD Population

Phase III Planning Under Way

 
• By Mandy Jackson

Anti-TSLP antibody Tezspire (tezepelumab) showed efficacy in a Phase IIa study versus placebo in COPD patients with lower eosinophil levels than those tested in Dupixent’s pivotal studies.

Human Respiratory System Lungs Anatomy. Man silhouette healthy lungs medicine model.
Tezspire showed greater efficacy in COPD patients with blood eosinophil counts of 150 or greater • Source: Shutterstock

More from Clinical Trials

More from R&D